source
- STAT+: Pharmalittle: We’re reading about upbeat results for a Duchenne drug, Takeda layoffs, and much moreBiogen reported mixed results from a mid-stage clinical trial investigating a treatment for Alzheimer’s disease that targets the protein tauSTAT · 2mo ago↗ source
- With new data, Regenxbio to seek FDA approval of Duchenne gene therapyThough two serious side effects muddied the results, CEO Curran Simpson expressed optimism about a clearance and claimed FDA leadership will have a “mandate on rare disease flexibility.”BioPharma Dive · 2mo ago↗ source
- How Penn Medicine plans to use AI to train their doctorsPhysicians at Penn Medicine said they're thinking of how to use AI to train doctors. The idea came out of a $1.1 million grant Penn Medicine won in January through an education grant program with ...